Header Logo

Connection

RAMMURTI KAMBLE to Female

Back to Details
This is a "connection" page, showing publications RAMMURTI KAMBLE has written about Female.
RAMMURTI KAMBLE
Connection Strength
0.626
Female
  1. Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. Transpl Infect Dis. 2019 Oct; 21(5):e13145.
    View in: PubMed
    Score: 0.026
  2. Voriconazole photosensitivity causes apparent graft-versus-host disease exacerbation. Bone Marrow Transplant. 2019 02; 54(2):323-325.
    View in: PubMed
    Score: 0.024
  3. Neuropathic dermatomes and cutaneous ulceration in patients with chronic GVHD. Bone Marrow Transplant. 2014 Jul; 49(7):986-7.
    View in: PubMed
    Score: 0.018
  4. Efficacy of deferred dosing of granulocyte colony-stimulating factor in autologous hematopoietic transplantation for multiple myeloma. Bone Marrow Transplant. 2014 Feb; 49(2):219-22.
    View in: PubMed
    Score: 0.017
  5. Orthotopic heart transplant facilitated autologous hematopoietic stem cell transplantation in light-chain amyloidosis. Methodist Debakey Cardiovasc J. 2012 Jul-Sep; 8(3):17-8.
    View in: PubMed
    Score: 0.016
  6. Systemic effects of oral budesonide in hematopoietic transplant: implications of drug interaction with azoles. Bone Marrow Transplant. 2012 Oct; 47(10):1370-1.
    View in: PubMed
    Score: 0.015
  7. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol. 2011 Nov; 86(11):961-2.
    View in: PubMed
    Score: 0.015
  8. Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 Jun; 39(11):705-9.
    View in: PubMed
    Score: 0.011
  9. Central nervous system graft-versus-host disease: report of two cases and literature review. Bone Marrow Transplant. 2007 Jan; 39(1):49-52.
    View in: PubMed
    Score: 0.011
  10. Rituximab responsive refractory acute graft-versus-host disease. Biol Blood Marrow Transplant. 2006 Nov; 12(11):1201-2.
    View in: PubMed
    Score: 0.011
  11. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006 May; 12(5):506-10.
    View in: PubMed
    Score: 0.010
  12. Increased mean corpuscular volume after autologous hematopoietic stem cell transplantation: incidence and significance. Biol Blood Marrow Transplant. 2006 Jan; 12(1):111-2.
    View in: PubMed
    Score: 0.010
  13. Malignant pleural effusion of multiple myeloma: prognostic factors and outcome. Leuk Lymphoma. 2005 Aug; 46(8):1137-42.
    View in: PubMed
    Score: 0.010
  14. Re: failure to engraft after autologous stem cell transplantation: possible therapeutic role of cyclosporine. Biol Blood Marrow Transplant. 2005 Jan; 11(1):74.
    View in: PubMed
    Score: 0.009
  15. Efficacy of Letermovir for Cytomegalovirus Prophylaxis Following Alemtuzumab T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant. Transplant Cell Ther. 2024 Dec; 30(12):1193.e1-1193.e8.
    View in: PubMed
    Score: 0.009
  16. Late effects after allogeneic haematopoietic cell transplantation in children and adolescents with non-malignant disorders: a retrospective cohort study. Lancet Child Adolesc Health. 2024 10; 8(10):740-750.
    View in: PubMed
    Score: 0.009
  17. Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplant Cell Ther. 2022 10; 28(10):681-693.
    View in: PubMed
    Score: 0.008
  18. Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome. J Clin Oncol. 2021 10 20; 39(30):3328-3339.
    View in: PubMed
    Score: 0.007
  19. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 05 13; 137(19):2585-2597.
    View in: PubMed
    Score: 0.007
  20. Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood. 2021 01 28; 137(4):556-568.
    View in: PubMed
    Score: 0.007
  21. T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects. J Clin Oncol. 2021 05 01; 39(13):1415-1425.
    View in: PubMed
    Score: 0.007
  22. Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452.
    View in: PubMed
    Score: 0.007
  23. Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer. 2021 02 15; 127(4):609-618.
    View in: PubMed
    Score: 0.007
  24. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer. 2021 01 01; 127(1):82-92.
    View in: PubMed
    Score: 0.007
  25. Safety Analysis of Five Randomized Controlled Studies of Daratumumab in Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2020 09; 20(9):e579-e589.
    View in: PubMed
    Score: 0.007
  26. Collection of Peripheral Blood Progenitor Cells in 1 Day Is Associated with Decreased Donor Toxicity Compared to 2 Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020 06; 26(6):1210-1217.
    View in: PubMed
    Score: 0.007
  27. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
    View in: PubMed
    Score: 0.007
  28. Delayed autologous stem cell transplantation following cardiac transplantation experience in patients with cardiac amyloidosis. Am J Transplant. 2019 10; 19(10):2900-2909.
    View in: PubMed
    Score: 0.006
  29. Inferior Outcomes with Cyclosporine and Mycophenolate Mofetil after Myeloablative Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1744-1755.
    View in: PubMed
    Score: 0.006
  30. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 09; 25(9):1875-1883.
    View in: PubMed
    Score: 0.006
  31. Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019 05; 54(5):648-661.
    View in: PubMed
    Score: 0.006
  32. The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. Blood Adv. 2019 02 26; 3(4):670-680.
    View in: PubMed
    Score: 0.006
  33. The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. Biol Blood Marrow Transplant. 2019 07; 25(7):1325-1330.
    View in: PubMed
    Score: 0.006
  34. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. Biol Blood Marrow Transplant. 2019 04; 25(4):683-688.
    View in: PubMed
    Score: 0.006
  35. Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival. Biol Blood Marrow Transplant. 2019 02; 25(2):270-278.
    View in: PubMed
    Score: 0.006
  36. In?Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Mol Ther. 2018 12 05; 26(12):2727-2737.
    View in: PubMed
    Score: 0.006
  37. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):73-85.
    View in: PubMed
    Score: 0.006
  38. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. Biol Blood Marrow Transplant. 2018 12; 24(12):2443-2449.
    View in: PubMed
    Score: 0.006
  39. Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants. Blood Adv. 2018 05 08; 2(9):1022-1031.
    View in: PubMed
    Score: 0.006
  40. Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biol Blood Marrow Transplant. 2018 09; 24(9):1928-1935.
    View in: PubMed
    Score: 0.006
  41. Donor body mass index does not predict graft versus host disease following hematopoietic cell transplantation. Bone Marrow Transplant. 2018 07; 53(7):932-937.
    View in: PubMed
    Score: 0.006
  42. Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant. 2018 06; 24(6):1163-1171.
    View in: PubMed
    Score: 0.006
  43. Influence of Age on Acute and Chronic GVHD in Children Undergoing HLA-Identical Sibling Bone Marrow Transplantation for Acute Leukemia: Implications for Prophylaxis. Biol Blood Marrow Transplant. 2018 03; 24(3):521-528.
    View in: PubMed
    Score: 0.006
  44. Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica. 2017 11; 102(11):1823-1832.
    View in: PubMed
    Score: 0.006
  45. Granulocytic sarcoma of uterine cervix as presentation of acute myeloid leukemia: a case report and review of literature. J Obstet Gynaecol Res. 1997 Jun; 23(3):261-6.
    View in: PubMed
    Score: 0.005
  46. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less than Three Years of Age. Biol Blood Marrow Transplant. 2017 Aug; 23(8):1327-1334.
    View in: PubMed
    Score: 0.005
  47. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2017 Aug; 23(8):1320-1326.
    View in: PubMed
    Score: 0.005
  48. Improved survival after acute graft-versus-host disease diagnosis in the modern era. Haematologica. 2017 05; 102(5):958-966.
    View in: PubMed
    Score: 0.005
  49. Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer. 2017 05 15; 123(10):1828-1838.
    View in: PubMed
    Score: 0.005
  50. Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Feb; 23(2):269-277.
    View in: PubMed
    Score: 0.005
  51. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014.
    View in: PubMed
    Score: 0.005
  52. Clinical responses with T lymphocytes targeting malignancy-associated ? light chains. J Clin Invest. 2016 07 01; 126(7):2588-96.
    View in: PubMed
    Score: 0.005
  53. Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol. 2016 06 01; 34(16):1864-71.
    View in: PubMed
    Score: 0.005
  54. Cutaneous metastases of lung cancer. Postgrad Med J. 1995 Dec; 71(842):741-3.
    View in: PubMed
    Score: 0.005
  55. Significant Improvements in the Practice Patterns of Adult Related Donor Care in US Transplantation Centers. Biol Blood Marrow Transplant. 2016 Mar; 22(3):520-7.
    View in: PubMed
    Score: 0.005
  56. Outcomes of Allogeneic Hematopoietic Cell Transplantation in?Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biol Blood Marrow Transplant. 2016 Mar; 22(3):432-40.
    View in: PubMed
    Score: 0.005
  57. Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma. Bone Marrow Transplant. 2016 Jan; 51(1):58-66.
    View in: PubMed
    Score: 0.005
  58. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 Nov 10; 33(32):3741-9.
    View in: PubMed
    Score: 0.005
  59. Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. Biol Blood Marrow Transplant. 2016 Feb; 22(2):248-257.
    View in: PubMed
    Score: 0.005
  60. Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Dec; 50(12):1513-8.
    View in: PubMed
    Score: 0.005
  61. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015 Nov; 50(11):1416-23.
    View in: PubMed
    Score: 0.005
  62. Analysis of the Effect of Race, Socioeconomic Status, and Center Size on Unrelated National Marrow Donor Program Donor Outcomes: Donor Toxicities Are More Common at Low-Volume Bone Marrow Collection Centers. Biol Blood Marrow Transplant. 2015 Oct; 21(10):1830-8.
    View in: PubMed
    Score: 0.005
  63. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015 Jun 25; 125(26):4103-13.
    View in: PubMed
    Score: 0.005
  64. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015 Aug; 50(8):1013-23.
    View in: PubMed
    Score: 0.005
  65. New cancers after autotransplantations for multiple myeloma. Biol Blood Marrow Transplant. 2015 Apr; 21(4):738-45.
    View in: PubMed
    Score: 0.005
  66. Comparison of outcomes of allogeneic transplantation for chronic myeloid leukemia with cyclophosphamide in combination with intravenous busulfan, oral busulfan, or total body irradiation. Biol Blood Marrow Transplant. 2015 Mar; 21(3):552-8.
    View in: PubMed
    Score: 0.005
  67. Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor. Bone Marrow Transplant. 2015 Feb; 50(2):197-203.
    View in: PubMed
    Score: 0.005
  68. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015 Jan; 21(1):151-8.
    View in: PubMed
    Score: 0.005
  69. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71.
    View in: PubMed
    Score: 0.005
  70. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1777-84.
    View in: PubMed
    Score: 0.004
  71. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1729-36.
    View in: PubMed
    Score: 0.004
  72. Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens. Biol Blood Marrow Transplant. 2014 Sep; 20(9):1390-8.
    View in: PubMed
    Score: 0.004
  73. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014 Apr; 20(4):587-92.
    View in: PubMed
    Score: 0.004
  74. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma. Biol Blood Marrow Transplant. 2014 Mar; 20(3):402-408.e1.
    View in: PubMed
    Score: 0.004
  75. Does total body irradiation conditioning improve outcomes of myeloablative human leukocyte antigen-identical sibling transplantations for chronic lymphocytic leukemia? Biol Blood Marrow Transplant. 2014 Mar; 20(3):421-4.
    View in: PubMed
    Score: 0.004
  76. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. Biol Blood Marrow Transplant. 2014 Feb; 20(2):202-8.
    View in: PubMed
    Score: 0.004
  77. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2014 Jan; 20(1):89-97.
    View in: PubMed
    Score: 0.004
  78. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013 Dec 05; 122(24):3863-70.
    View in: PubMed
    Score: 0.004
  79. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013 Oct 24; 122(17):2965-73.
    View in: PubMed
    Score: 0.004
  80. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1615-24.
    View in: PubMed
    Score: 0.004
  81. Physician perceptions and practice patterns regarding fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2013 Aug; 48(8):1091-7.
    View in: PubMed
    Score: 0.004
  82. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. Biol Blood Marrow Transplant. 2013 May; 19(5):746-53.
    View in: PubMed
    Score: 0.004
  83. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2013 Apr; 19(4):625-31.
    View in: PubMed
    Score: 0.004
  84. Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
    View in: PubMed
    Score: 0.004
  85. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013 Mar; 48(3):363-8.
    View in: PubMed
    Score: 0.004
  86. Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1776-84.
    View in: PubMed
    Score: 0.004
  87. Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. Bone Marrow Transplant. 2012 Jun; 47(6):831-7.
    View in: PubMed
    Score: 0.004
  88. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011 Aug 18; 118(7):1979-88.
    View in: PubMed
    Score: 0.004
  89. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1765-74.
    View in: PubMed
    Score: 0.004
  90. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011 May; 121(5):1822-6.
    View in: PubMed
    Score: 0.004
  91. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 Aug 10; 28(23):3730-8.
    View in: PubMed
    Score: 0.003
  92. Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2010 Mar; 16(3):395-402.
    View in: PubMed
    Score: 0.003
  93. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2009 Nov; 15(11):1455-64.
    View in: PubMed
    Score: 0.003
  94. Expression of the vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukemia: incidence and feasibility of immunohistochemical staining. Clin Lab Haematol. 2006 Aug; 28(4):254-8.
    View in: PubMed
    Score: 0.003
  95. Cytogenetic changes associated with myelodysplastic syndrome affecting bone marrow engraftment analysis. J Mol Diagn. 2006 May; 8(2):288-94.
    View in: PubMed
    Score: 0.003
  96. Symptomatic metastases to the pituitary infundibulum resulting from primary breast cancer. Int J Clin Oncol. 2005 Jun; 10(3):191-4.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.